Biologic Specimen and Data Repository Information Coordinating Center
Home > Proprietary Studies > BMT CTN 0401

Resources Available

Specimens Only

Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkin's Lymphoma (BMT CTN 0401)

Website: https://web.emmes.com/study/bmt2
Parent Study Contact: Alan Howard, ahoward@nmdp.org
Study Type: Clinical Trial
Prepared on May 31, 2012
Consent: Restricted Consent
Consent Restrictions: For protocol use only
Commercial Use Restrictions: No
Collection Type: Proprietary Study - See bottom of this webpage for request information

Objectives

The primary objective of this study is to compare progression-free survival (PFS) after autologous Hematopoietic stem cell transplantation (ASCT) for chemotherapy-sensitive diffuse large B-cell lymphoma using Rituxan/BEAM versus Bexxar/BEAM for pre-transplant conditioning.

Interested parties can contact Alan Howard for further details about specimen availability.


Interested parties should review the Proprietary Study application process before they begin. Requests for Proprietary Studies must be approved by the Parent Study before they can be processed by BioLINCC. Contact information for the Parent Study is provided at the top of this webpage. Upon Parent Study approval, click the Request button to start a request through BioLINCC.